3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Phase 1/2
1
Status
Withdrawn
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Breast
1
Conditions
Breast Neoplasms
11
Sarcoma
3
Triple Negative Breast Neoplasms
2
Neoplasm Metastasis
2
Urinary Bladder Neoplasms
1
Sarcoma, Ewing
1
Rhabdomyosarcoma
1
Neoplasms
1
Melanoma
1
Lung Neoplasms
1
Liposarcoma
1
Leiomyosarcoma
1
Inoperable Locally Advanced HER2-Negative Breast Cancer
1
Inflammatory Breast Neoplasms
1
HR Positive HER2 Negative Advanced Breast Cancer
1
HER-2 Positive Breast Cancer
1
Diabetes Mellitus, Insulin-Dependent, 12
1
Colorectal Neoplasms
1
Carcinoma, Transitional Cell
1
Carcinoma, Renal Cell
1
Carcinoma, Non-Small-Cell Lung
1
Carcinoma, Hepatocellular
1
Carcinoma
1
Brain Neoplasms
1
Advanced Breast Cancer
1
Interventions
sacituzumab govitecan
1
eribulin
1
balixafortide
1
Taxes
1
Albumin-Bound Paclitaxel
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 1/2
×
Advanced Breast Cancer
×
eribulin
×
Clear all
NCT04826016
2023-03-20
POLTER
MedSIR
Phase 1/2
Withdrawn